KalVista Pharmaceuticals, Inc. Quarterly Accrued Liabilities, Current in USD from Q4 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
KalVista Pharmaceuticals, Inc. quarterly Accrued Liabilities, Current history and growth rate from Q4 2014 to Q2 2024.
  • KalVista Pharmaceuticals, Inc. Accrued Liabilities, Current for the quarter ending July 31, 2024 was $10.4M, a 30.3% increase year-over-year.
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $10.4M +$2.41M +30.3% Jul 31, 2024 10-Q 2024-09-05
Q1 2024 $12.4M +$3.27M +35.8% Apr 30, 2024 10-Q 2024-09-05
Q4 2023 $14.8M +$5.99M +67.7% Jan 31, 2024 10-Q 2024-03-11
Q3 2023 $11.7M +$4.8M +69.4% Oct 31, 2023 10-Q 2023-12-07
Q2 2023 $7.95M +$2.12M +36.4% Jul 31, 2023 10-Q 2023-09-07
Q1 2023 $9.13M +$2.17M +31.1% Apr 30, 2023 10-K 2024-07-11
Q4 2022 $8.85M +$2.4M +37.2% Jan 31, 2023 10-Q 2023-03-09
Q3 2022 $6.91M +$885K +14.7% Oct 31, 2022 10-Q 2022-12-08
Q2 2022 $5.83M -$48K -0.82% Jul 31, 2022 10-Q 2022-09-08
Q1 2022 $6.96M +$31K +0.45% Apr 30, 2022 10-K 2023-07-10
Q4 2021 $6.45M +$1.17M +22% Jan 31, 2022 10-Q 2022-03-10
Q3 2021 $6.03M -$916K -13.2% Oct 31, 2021 10-Q 2021-12-09
Q2 2021 $5.88M -$294K -4.77% Jul 31, 2021 10-Q 2021-09-09
Q1 2021 $6.93M +$1.48M +27% Apr 30, 2021 10-K 2022-07-07
Q4 2020 $5.29M +$409K +8.39% Jan 31, 2021 10-Q 2021-03-11
Q3 2020 $6.94M +$1.91M +38% Oct 31, 2020 10-Q 2020-12-10
Q2 2020 $6.17M +$1.91M +44.8% Jul 31, 2020 10-Q 2020-09-14
Q1 2020 $5.46M -$192K -3.4% Apr 30, 2020 10-K 2021-07-13
Q4 2019 $4.88M +$1.47M +43.1% Jan 31, 2020 10-Q 2020-03-10
Q3 2019 $5.03M +$2.04M +68% Oct 31, 2019 10-Q 2019-12-03
Q2 2019 $4.26M +$1.12M +35.8% Jul 31, 2019 10-Q 2019-09-09
Q1 2019 $5.65M +$2.56M +82.9% Apr 30, 2019 10-K 2020-07-01
Q4 2018 $3.41M +$1.12M +48.8% Jan 31, 2019 10-Q 2019-03-14
Q3 2018 $2.99M +$741K +32.9% Oct 31, 2018 10-Q 2018-12-14
Q2 2018 $3.14M +$1.45M +85.4% Jul 31, 2018 10-Q 2018-09-14
Q1 2018 $3.09M +$1.22M +65.5% Apr 30, 2018 10-K 2019-07-16
Q4 2017 $2.29M -$156K -6.38% Jan 31, 2018 10-Q 2018-03-16
Q3 2017 $2.25M +$822K +57.4% Oct 31, 2017 10-Q 2017-12-14
Q2 2017 $1.69M -$21K -1.23% Jul 31, 2017 10-Q 2017-09-14
Q1 2017 $1.87M +$783K +72.4% Apr 30, 2017 10-K 2018-07-30
Q4 2016 $2.45M +$1.12M +84.3% Jan 31, 2017 10-Q 2017-03-16
Q3 2016 $1.43M +$159K +12.5% Sep 30, 2016 10-Q 2016-11-08
Q2 2016 $1.71M +$47K +2.82% Jun 30, 2016 10-Q 2016-08-12
Q1 2016 $1.08M -$750K -40.9% Mar 31, 2016 10-Q 2016-05-12
Q4 2015 $1.33M -$278K -17.3% Dec 31, 2015 10-Q 2016-11-08
Q3 2015 $1.27M Sep 30, 2015 10-Q 2015-11-12
Q2 2015 $1.67M Jun 30, 2015 10-Q 2015-08-13
Q1 2015 $1.83M Mar 31, 2015 10-Q 2015-05-21
Q4 2014 $1.61M Dec 31, 2014 10-K 2016-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.